nach oben

International Journal of Clinical Oncology

Erschienen in:

14.08.2015 | Original Article

Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy

verfasst von: Goshi Nishimura, Masanori Komatsu, Masaharu Hata, Kenichiro Yabuki, Takahide Taguchi, Masahiro Takahashi, Osamu Shiono, Daisuke Sano, Yasuhiro Arai, Hideaki Takahashi, Yoshihiro Chiba, Nobuhiko Oridate

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemoradiotherapy (CRT) is used to treat cervical lymph node(s) metastatic head and neck cancer patients. Evaluation and treatment of lymph node(s) after CRT is important to improve the prognosis.

Methods

Prior to CRT, we determined the TNM stage by visual and imaging examinations. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were calculated from the results of fluorodeoxyglucose-positron emission tomography (FDG-PET). After CRT, the patients were divided in two groups—complete response (CR) and non-CR—and their responses were compared with the clinical characteristics.

Results

T4, N2b, N2c and TLG_2.5 ≥18.8 were statistically significant predictive indices before CRT. The odds ratio, 95 % confidence interval and p value were, respectively—T4: 2.73, 1.15–6.51, 0.0230; N2b: 6.96, 1.50–32.3, 0.0132; N2c: 11.80, 2.37–58.50, 0.00258; and TLG_2.5 ≥18.8: 6.25, 2.17–18.00, 0.000672.

Conclusions

TLG was found to be a good predictive factor for metastatic lymph node(s) prior to CRT treatment. After CRT treatment, FDG-PET was found to be highly specific and useful for negative screening.

Urba SG, Moon J, Giri PG et al (2005) Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 23:88–95CrossRefPubMed

Fountzilas G, Ciuleanu E, Dafni U et al (2004) Concomitant radiochemotherapy vs. radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol 21:95–107CrossRefPubMed

Seiwert TY, Cohen EE (2005) State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92:1341–1348CrossRefPubMedPubMedCentral

Taguchi T, Ikeda Y, Mikami Y et al (2003) Combined radiotherapy and chemotherapy with carboplatin and UFT foe head and neck squamous cell carcinoma. Anticancer Res 23:713–717PubMed

Katori H, Tsukuda M, Mochimatsu I et al (2004) Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of head and neck (SCCHN). Br J Cancer 90:348–352CrossRefPubMedPubMedCentral

Fujii M, Tsukuda M, Satake B et al (2004) Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 9:107–112CrossRefPubMed

Taguchi T, Tsukuda M, Mikami Y et al (2006) Concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate, and leucovorin in patients with advanced resectable squamous cell carcinoma of the larynx and hypopharynx. Acta Otolaryngol 126:408–413CrossRefPubMed

Katori H, Tsukuda M, Taguchi T (2007) Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 59:789–794CrossRefPubMed

Katori H, Tsukuda M, Taguchi T (2007) Concurrent chemoradiotherapy with carboplatin and uracil-tegafur (UFT) for patients with poor performance status with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Acta Otolaryngol 127:1099–1104CrossRefPubMed

10.

Tsukuda M, Ishitoya J, Mikami Y et al (2009) Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol 64:945–952CrossRefPubMedPubMedCentral

11.

Tsukuda M, Ishitoya J, Matsuda H et al (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 66:729–736CrossRefPubMed

12.

Hermann RM, Christiansen H, Rödel RM (2013) Lymph node positive head and neck carcinoma after curative radiochemotherapy: a long lasting debate on elective post-therapeutic neck dissections comes to conclusion. Cancer Radiother 17:323–331CrossRefPubMed

13.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMedPubMedCentral

14.

Schöder H, Fury M, Lee N et al (2009) PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50:74S–88SCrossRefPubMed

15.

Parsons JT, Mendenhall WM, Stringer SP et al (2002) Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 94:2967–2980CrossRefPubMed

16.

Brizel DM, Prosnitz RG, Hunter S et al (2004) Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 58:1418–1423CrossRefPubMed

17.

Argiris A, Stenson KM, Brockstein BE et al (2004) Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 26:447–455CrossRefPubMed

18.

Lavertu P, Adelsetein DJ, Saxton JP et al (1997) Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 19:559–566CrossRefPubMed

19.

Corry J, Peters L, Fisher R et al (2008) N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders—results of Trans Tasman Radiation Oncology Group Study 98.02. Head Neck 30:737–742CrossRefPubMed

20.

Peters LJ, Weber RS, Morrison WH et al (1996) Neck surgery in patients with primary oropharyngeal cancer treated by radiotherapy. Head Neck 18:552–559CrossRefPubMed

21.

Nishimura G, Matsuda H, Tagushi T et al (2012) Treatment evaluation of metastatic lymph nodes after concurrent chemoradiotherapy in patients with head and neck squamous cell carcinoma. Anticancer Res 32:595–600PubMed

22.

Yabuki Y, Shiono O, Komatsu M et al (2015) Predictive and prognostic value of metabolic tumor volume (MTV) in patients with laryngeal carcinoma treated by radiotherapy (RT)/concurrent chemoradiotherapy (CCRT). PLoS One 10:e0117924CrossRefPubMedPubMedCentral

23.

Picchio M, Kirienko M, Mapelli P et al (2014) Predictive value of pre-therapy ¹⁸F-FDG PET/CT for the outcome of ¹⁸F-FGD PET-guided radiotherapy in patients with head and neck cancer. Eur J Necl Med Mol Imaging 41:21–31CrossRef

24.

Schinagl DA, Span PN, Oyen WJ et al (2011) Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. Eur J Nucl Med Mol Imaging 38:1449–1458CrossRefPubMedPubMedCentral

25.

Hatt M, Le Pogam A, Visvikis D et al (2012) Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med 53:12–20CrossRefPubMedPubMedCentral

26.

Larson SM, Erdi Y, Akhurst T et al (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. Clin Positron Imaging 2:159–171CrossRefPubMed

27.

Van de Wiele C, Kruse V, Smeets P et al (2013) Predictive and prognostic value of metabolic tumor volume and total lesion glycolysis in solid tumors. Eur J Nucl Med Mol Imaging 40:290–301CrossRefPubMed

Titel: Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy
verfasst von: Goshi Nishimura
Masanori Komatsu
Masaharu Hata
Kenichiro Yabuki
Takahide Taguchi
Masahiro Takahashi
Osamu Shiono
Daisuke Sano
Yasuhiro Arai
Hideaki Takahashi
Yoshihiro Chiba
Nobuhiko Oridate
Publikationsdatum: 14.08.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0890-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Development and future directions of antiangiogenic therapy in hepatocellular carcinoma

Relationship between quality of life instruments and phonatory function in tracheoesophageal speech with voice prosthesis

Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers

Tumor angiogenesis—characteristics of tumor endothelial cells

Prognostic factors after imatinib secondary resistance: survival analysis in patients with unresectable and metastatic gastrointestinal stromal tumors

The processus vaginalis transection method is superior to the simple prophylactic procedure for prevention of inguinal hernia after radical prostatectomy

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie